NextCure Historical Balance Sheet

NXTC Stock

USD 0.57 0.04 6.56%

Trend analysis of NextCure balance sheet accounts such as Total Current Liabilities of 9.8 M provides information on NextCure's total assets, liabilities, and equity, which is the actual value of NextCure to its prevalent stockholders. By breaking down trends over time using NextCure balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining NextCure latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NextCure is a good buy for the upcoming year.

NextCure Inventory

(598,500)

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.

About NextCure Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of NextCure at a specified time, usually calculated after every quarter, six months, or one year. NextCure Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of NextCure and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which NextCure currently owns. An asset can also be divided into two categories, current and non-current.

NextCure Balance Sheet Chart

At present, NextCure's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 9.8 M, whereas Short and Long Term Debt Total is forecasted to decline to about 4.6 M.

Total Assets Short Long Term Debt Total Other Current Liab Capital Lease Obligations

Add Fundamental

Total Assets

Total assets refers to the total amount of NextCure assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in NextCure books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Capital Lease Obligations

NextCure capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to NextCure asset purchases. For example, NextCure can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as NextCure control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.

Most accounts from NextCure's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into NextCure current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.At present, NextCure's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 9.8 M, whereas Short and Long Term Debt Total is forecasted to decline to about 4.6 M.

	2023	2024	2025 (projected)
Short and Long Term Debt Total	6.6M	5.2M	4.6M
Total Assets	128.0M	80.9M	146.5M

Short Long Term Debt Total Total Assets

NextCure balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity
Total Assets		0.67	0.88	0.88	0.94	0.48	0.89	0.72	0.63	-0.3	-0.35	0.48	0.34	0.82	0.61	0.82	0.82	1.0	0.74	0.62	0.82	-0.21	0.75	0.13	0.76	0.54
Short Long Term Debt Total	0.67		0.9	0.61	0.76	-0.01	0.84	0.7	0.16	0.1	-0.81	0.64	-0.04	0.73	0.78	0.48	0.84	0.66	0.93	0.91	0.84	-0.58	0.94	0.69	0.92	0.88
Other Current Liab	0.88	0.9		0.83	0.91	0.16	0.98	0.72	0.35	-0.06	-0.73	0.72	0.12	0.8	0.69	0.65	0.93	0.87	0.96	0.89	0.93	-0.52	0.96	0.48	0.91	0.83
Total Current Liabilities	0.88	0.61	0.83		0.74	0.62	0.8	0.54	0.76	-0.5	-0.52	0.67	0.55	0.68	0.55	0.72	0.8	0.88	0.74	0.58	0.8	-0.05	0.74	0.33	0.59	0.5
Total Stockholder Equity	0.94	0.76	0.91	0.74		0.19	0.95	0.71	0.39	0.02	-0.4	0.47	0.02	0.8	0.65	0.81	0.89	0.93	0.82	0.71	0.89	-0.51	0.83	0.21	0.83	0.64
Other Liab	0.48	-0.01	0.16	0.62	0.19		0.13	0.05	0.95	-0.85	0.13	0.05	0.85	0.15	0.11	0.37	0.18	0.49	0.03	-0.14	0.18	0.68	0.04	-0.18	0.01	-0.2
Net Tangible Assets	0.89	0.84	0.98	0.8	0.95	0.13		0.67	0.34	0.03	-0.64	0.64	0.03	0.76	0.64	0.69	0.95	0.88	0.94	0.83	0.95	-0.58	0.94	0.39	0.88	0.77
Property Plant And Equipment Net	0.72	0.7	0.72	0.54	0.71	0.05	0.67		0.13	-0.12	-0.47	0.49	0.16	0.97	0.79	0.63	0.52	0.71	0.64	0.72	0.52	-0.32	0.65	0.39	0.73	0.69
Current Deferred Revenue	0.63	0.16	0.35	0.76	0.39	0.95	0.34	0.13		-0.69	0.03	0.12	0.7	0.28	0.21	0.55	0.43	0.64	0.21	-0.02	0.43	0.45	0.22	-0.1	0.14	-0.1
Net Debt	-0.3	0.1	-0.06	-0.5	0.02	-0.85	0.03	-0.12	-0.69		-0.01	-0.26	-1.0	-0.12	-0.09	-0.14	0.09	-0.32	0.02	0.05	0.09	-0.81	0.02	0.07	0.05	0.06
Retained Earnings	-0.35	-0.81	-0.73	-0.52	-0.4	0.13	-0.64	-0.47	0.03	-0.01		-0.79	-0.05	-0.48	-0.59	-0.09	-0.61	-0.35	-0.83	-0.87	-0.61	0.47	-0.82	-0.85	-0.68	-0.87
Accounts Payable	0.48	0.64	0.72	0.67	0.47	0.05	0.64	0.49	0.12	-0.26	-0.79		0.31	0.52	0.55	0.38	0.57	0.47	0.8	0.81	0.57	-0.26	0.78	0.71	0.55	0.81
Cash	0.34	-0.04	0.12	0.55	0.02	0.85	0.03	0.16	0.7	-1.0	-0.05	0.31		0.17	0.16	0.18	-0.03	0.35	0.04	0.01	-0.03	0.77	0.04	0.0	-0.01	0.0
Non Current Assets Total	0.82	0.73	0.8	0.68	0.8	0.15	0.76	0.97	0.28	-0.12	-0.48	0.52	0.17		0.82	0.77	0.67	0.81	0.7	0.71	0.67	-0.35	0.72	0.41	0.72	0.66
Non Currrent Assets Other	0.61	0.78	0.69	0.55	0.65	0.11	0.64	0.79	0.21	-0.09	-0.59	0.55	0.16	0.82		0.56	0.61	0.6	0.72	0.75	0.61	-0.3	0.75	0.7	0.65	0.74
Other Assets	0.82	0.48	0.65	0.72	0.81	0.37	0.69	0.63	0.55	-0.14	-0.09	0.38	0.18	0.77	0.56		0.7	0.82	0.53	0.37	0.7	-0.22	0.55	0.13	0.44	0.29
Long Term Debt	0.82	0.84	0.93	0.8	0.89	0.18	0.95	0.52	0.43	0.09	-0.61	0.57	-0.03	0.67	0.61	0.7		0.81	0.9	0.73	1.0	-0.58	0.9	0.45	0.77	0.65
Cash And Short Term Investments	1.0	0.66	0.87	0.88	0.93	0.49	0.88	0.71	0.64	-0.32	-0.35	0.47	0.35	0.81	0.6	0.82	0.81		0.73	0.61	0.81	-0.2	0.74	0.11	0.75	0.53
Common Stock Total Equity	0.74	0.93	0.96	0.74	0.82	0.03	0.94	0.64	0.21	0.02	-0.83	0.8	0.04	0.7	0.72	0.53	0.9	0.73		0.95	0.9	-0.58	1.0	0.65	0.89	0.91
Common Stock Shares Outstanding	0.62	0.91	0.89	0.58	0.71	-0.14	0.83	0.72	-0.02	0.05	-0.87	0.81	0.01	0.71	0.75	0.37	0.73	0.61	0.95		0.73	-0.58	0.95	0.7	0.89	0.99
Long Term Debt Total	0.82	0.84	0.93	0.8	0.89	0.18	0.95	0.52	0.43	0.09	-0.61	0.57	-0.03	0.67	0.61	0.7	1.0	0.81	0.9	0.73		-0.58	0.9	0.45	0.77	0.65
Non Current Liabilities Total	-0.21	-0.58	-0.52	-0.05	-0.51	0.68	-0.58	-0.32	0.45	-0.81	0.47	-0.26	0.77	-0.35	-0.3	-0.22	-0.58	-0.2	-0.58	-0.58	-0.58		-0.58	-0.37	-0.55	-0.55
Capital Surpluse	0.75	0.94	0.96	0.74	0.83	0.04	0.94	0.65	0.22	0.02	-0.82	0.78	0.04	0.72	0.75	0.55	0.9	0.74	1.0	0.95	0.9	-0.58		0.65	0.89	0.91
Capital Lease Obligations	0.13	0.69	0.48	0.33	0.21	-0.18	0.39	0.39	-0.1	0.07	-0.85	0.71	0.0	0.41	0.7	0.13	0.45	0.11	0.65	0.7	0.45	-0.37	0.65		0.41	0.72
Other Current Assets	0.76	0.92	0.91	0.59	0.83	0.01	0.88	0.73	0.14	0.05	-0.68	0.55	-0.01	0.72	0.65	0.44	0.77	0.75	0.89	0.89	0.77	-0.55	0.89	0.41		0.86
Other Stockholder Equity	0.54	0.88	0.83	0.5	0.64	-0.2	0.77	0.69	-0.1	0.06	-0.87	0.81	0.0	0.66	0.74	0.29	0.65	0.53	0.91	0.99	0.65	-0.55	0.91	0.72	0.86

Click cells to compare fundamentals

NextCure Account Relationship Matchups

NextCure balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	306.6M	242.4M	184.2M	128.0M	80.9M	146.5M
Short Long Term Debt Total	5.1M	3.5M	7.1M	6.6M	5.2M	4.6M
Other Current Liab	4.8M	4.7M	4.3M	3.9M	4.2M	4.3M
Total Current Liabilities	10.3M	6.6M	9.1M	6.9M	9.6M	9.8M
Total Stockholder Equity	293.7M	233.4M	167.5M	114.4M	65.5M	62.2M
Other Liab	16.3M	792K	2.4M	899K	809.1K	768.6K
Net Tangible Assets	321.5M	293.7M	233.4M	167.5M	192.7M	173.2M
Property Plant And Equipment Net	15.8M	14.0M	16.9M	13.4M	8.7M	14.1M
Net Debt	(29.3M)	(12.3M)	(19.5M)	(6.5M)	(22.6M)	(23.7M)
Retained Earnings	(117.6M)	(187.0M)	(261.8M)	(324.5M)	(380.1M)	(361.1M)
Accounts Payable	3.9M	1.9M	4.3M	2.3M	5.4M	3.2M
Cash	32.8M	12.3M	26.6M	13.1M	27.7M	29.0M
Non Current Assets Total	18.7M	14.6M	20.2M	15.3M	9.1M	15.9M
Non Currrent Assets Other	1.1M	577K	1.7M	1.9M	332K	315.4K
Other Assets	436K	4.1M	2.9M	577K	3.3M	0.0
Cash And Short Term Investments	283.4M	219.6M	159.9M	108.3M	68.6M	131.8M
Common Stock Shares Outstanding	27.5M	27.6M	27.7M	27.8M	28.0M	24.0M
Short Term Investments	250.7M	207.3M	133.3M	95.2M	40.9M	38.8M
Liabilities And Stockholders Equity	306.6M	242.4M	184.2M	128.0M	80.9M	146.5M
Non Current Liabilities Total	2.6M	2.4M	7.5M	6.7M	5.8M	5.5M
Capital Surpluse	402.5M	410.6M	421.0M	430.8M	495.4M	305.3M
Other Current Assets	4.5M	8.2M	4.1M	4.4M	3.2M	3.9M
Other Stockholder Equity	410.6M	421.0M	430.8M	439.1M	445.6M	302.1M
Total Liab	12.9M	9M	16.6M	13.6M	15.4M	14.6M
Net Invested Capital	297.2M	233.4M	167.5M	114.4M	65.5M	62.2M
Property Plant And Equipment Gross	15.8M	26.7M	33.5M	33.7M	31.8M	24.1M
Total Current Assets	288.0M	227.8M	164.0M	112.7M	71.8M	135.0M
Accumulated Other Comprehensive Income	779K	(663K)	(1.5M)	(222K)	4K	4.2K
Net Working Capital	277.7M	221.2M	154.9M	105.8M	62.2M	59.1M
Short Term Debt	1.8M	1.7M	518K	656K	754.4K	1.0M
Property Plant Equipment	12.1M	15.8M	14.0M	11.9M	13.7M	13.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:

How To Invest In NextCure

Details

Is NextCure Stock a good investment?

Details

What is NextCure's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.

You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.99)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.34)

Return On Equity

(0.62)

The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NextCure Historical Balance Sheet

NextCure Inventory

(598,500)

About NextCure Balance Sheet Analysis

NextCure Balance Sheet Chart

Total Assets

Capital Lease Obligations

NextCure balance sheet Correlations

NextCure Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NextCure balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Long Term Debt Total	+ 1.0	Long Term Debt
Capital Surpluse	+ 1.0	Common Stock Total Equity
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Net Tangible Assets	+ 0.98	Other Current Liab
Non Current Assets Total	+ 0.97	Property Plant And Equipment Net

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.87	Retained Earnings
Common Stock Shares Outstanding	- 0.87	Retained Earnings
Capital Lease Obligations	- 0.85	Retained Earnings
Net Debt	- 0.85	Other Liab
Common Stock Total Equity	- 0.83	Retained Earnings